AVDL - Avadel Pharmaceuticals plc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

782.2M

Cash

160.5M

Avg Qtr Burn

-21.11M

Short % of Float

4.87%

Insider Ownership

4.98%

Institutional Own.

63.74%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUMRYZ (FT218) Details Solid tumor/s, Melanoma, Narcolepsy, Excessive daytime sleepiness, Cataplexy	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (FT218) Details Excessive daytime sleepiness, Narcolepsy	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.